STXBP1

STXBP1 Full Name

syntaxin binding protein 1

STXBP1 Introduction

Syntaxin binding protein 1 (STXBP1), also known as Munc18-1, is a member of the Sec1/Munc18 (SM) protein family that functions as an essential regulator of SNARE-mediated membrane fusion, particularly at neuronal synapses. Encoded by the STXBP1 gene on chromosome 9q34.11, STXBP1 is a predominantly neuronal protein that binds with high affinity to syntaxin-1, a Qa-SNARE protein of the presynaptic plasma membrane. STXBP1 plays a dual role in neurotransmitter release: it stabilizes syntaxin-1 in a closed conformation that prevents ectopic SNARE complex assembly, and it also promotes SNARE-mediated vesicle fusion through a distinct interaction mode during the exocytotic process.

Figure 1. Strcuture of STXBP1.

Dual Regulatory Roles in Synaptic Vesicle Exocytosis
The function of STXBP1 in neurotransmitter release is paradoxically both inhibitory and stimulatory. In its inhibitory mode, STXBP1 binds to the closed conformation of syntaxin-1, sequestering it from forming SNARE complexes with SNAP-25 and synaptobrevin/VAMP2, thereby preventing premature or ectopic membrane fusion. However, upon arrival of an action potential and calcium influx through voltage-gated calcium channels, STXBP1 transitions to a stimulatory mode: it interacts with the N-terminal peptide of syntaxin-1 to facilitate the transition of syntaxin-1 to its open conformation, enabling trans-SNARE complex assembly. STXBP1 also binds to the assembled SNARE complex through a domain 3a interaction surface, directly accelerating the rate of SNARE-mediated lipid mixing and fusion pore opening. This dual functionality ensures the precise spatiotemporal control of neurotransmitter release that underlies faithful synaptic transmission.

STXBP1 Encephalopathy and Neurodevelopmental Disorders
De novo heterozygous mutations in STXBP1 are among the most common genetic causes of developmental and epileptic encephalopathies (DEEs). STXBP1 encephalopathy (also known as STXBP1-related disorder) presents in early infancy with intractable epilepsy (often beginning with Ohtahara syndrome or infantile spasms), severe intellectual disability, motor dysfunction (ataxia, dystonia, hypotonia), and autism spectrum disorder features. The disorder follows a haploinsufficiency mechanism, with loss-of-function mutations reducing STXBP1 protein levels below the critical threshold for normal synaptic function. Over 200 distinct pathogenic mutations have been identified, distributed throughout the protein with some clustering in domain 3a (critical for SNARE complex binding). Current treatment is solely symptomatic with anti-epileptic medications; no disease-modifying therapy exists. Promising therapeutic avenues under preclinical investigation include antisense oligonucleotide-mediated upregulation of the remaining wild-type allele, pharmacological chaperones to stabilize mutant protein, and gene replacement therapy using AAV vectors.

Alternate Names for STXBP1

STXBP1; syntaxin binding protein 1; syntaxin-binding protein 1; hUNC18; MUNC18 1; rbSec1; UNC18; N-Sec1; unc-18A; unc18-1; neuronal SEC1; protein unc-18 homolog 1; protein unc-18 homolog A; P67; NSEC1; RBSEC1; MUNC18-1; FLJ37475;